Pharmaceuticals, Biotechnology and Life Sciences
Aura Biosciences said in a presentation at American Academy od Ophtalmology that its lead product candidate light-activated AU-011 has the potential to be the first FDA approved therapy for the primary treatment of choroidal melanoma.
Phase-1b/2 Clinical Data for Aura’s Lead Asset, AU-011, to be Highlighted at the Meeting and at Other Related Events CAMBRIDGE,…
Aura Biosciences’ lead productcandidate for the primary treatment of primary choroidal melanoma, willbe highlighted in a poster presentation at the Association for Researchin Vision and Ophthalmology (ARVO) 2019 Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that interim…